The histone methyltransferase enhancer of zeste homolog 2 (EZH2) is a target of MYB and both factors were downregulated by the EZH2 inhibitor EPZ011989 in AML cells via proteasomal degradation, which was accompanied by apoptosis induction and G2/M arrest. The gene discussed is MYB; the disease is acute myeloid leukemia.